All In Biotech

Drug Trial Radar · NCT07941544

Njinsky Ambispective Cellular Product Safety and Outcomes Registry

Safety and Disease-Specific Outcomes Following Routine-Care Use of Cultured UCMSCs and/or Autologous Uncultured SVF Across Multiple Indications: An Ambispective Observational Registry

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 30, 2030

Study completion Dec 30, 2032

Sponsor

Lead sponsor
Njinsky Medical CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This ambispective observational registry will describe safety events, treatment patterns, and disease-specific clinical assessments among patients receiving cultured umbilical cord mesenchymal stromal cells (UCMSCs), autologous uncultured stromal vascular fraction (SVF), or both as part of routine care at Njinsky Medical Centre. The registry includes separate cohorts for retinitis pigmentosa, autism spectrum disorder, female infertility conditions, and azoospermia. The retrospective component will use eligible routine-care records from 1 January 2020 through 30 November 2026. Prospective enrollment is planned from 1 December 2026 through 31 December 2030, with follow-up at 1, 3, 6, 12 and 24 months after the last treatment session. Patients may be followed by phone or in person. The study will not assign treatment or require additional tests; it will record measures obtained in routine care and information reported or documented at follow-up. Results will be described separately by condition and actual product exposure. The registry is not designed by itself to establish that a product caused a clinical outcome.

Conditions

  • Retinitis Pigmentosa (RP)
  • Autism Disorder
  • Diminished Ovarian Reserve
  • Azoospermia
  • Amenorrhea Secondary
  • Azoospermia, Nonobstructive

Interventions

  • Umbilical Cord Mesenchymal Stem CellsBiological

    Routine-care exposure observed by the registry. The study does not assign treatment. Cultured umbilical cord mesenchymal stromal cells are administered at 1 million cells/kg total. Half is given intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual dose, route, dates, and sessions are recorded.

  • Stromal Vascular fractionBiological

    Routine-care exposure observed by the registry. The study does not assign treatment. Autologous uncultured stromal vascular fraction is prepared from approximately 100 to 120 mL of adipose tissue. The resulting pellet is resuspended in saline. Half is administered intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual preparation, route, dates, and sessions are recorded.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants with one or more adverse effects reported or documented after administrationTime frame: During observation for up to 10 hours after each administration, and at follow-up 1, 3, 6, 12, and 24 months after the participant's last session.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Njinsky Medical Centre

    Lahore, Punjab Province, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.